Culturable Nasal Bacteria in Chronic Rhinosinusitis with Nasal Polyps: A Single-Center Observational Pilot Study
Diseases · 22.07.2026 · 14 (7) · 264
DOI: 10.3390/diseases14070264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases, online erschienen am 22.07.2026. Verfasst von Camilla Laureti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otolaryngology-Head and Neck Surgery, Ospedale San Camillo de Lellis, Azienda Sanitaria Locale (ASL) Rieti, Sapienza University of Rome, …. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bank of Italy.
Abstract (Originalsprache)
Background
Bacteria colonizing the nasal cavity contribute to mucosal homeostasis, and altered sinonasal bacterial communities have been associated with chronic rhinosinusitis with nasal polyps (CRSwNP). Whether routine, culture-based microbiology can distinguish the cultivable bacterial profile of CRSwNP patients from that of controls remains unclear.
Methods
In this single-center observational pilot study, middle-meatus swabs from 30 patients with CRSwNP and 30 controls were cultured on four media, and isolates were identified with the VITEK 2 system. For each species, presence or absence per subject was compared between groups using Fisher’s exact test with Benjamini–Hochberg correction for multiple comparisons; the number of cultivable species per subject was compared with the Mann–Whitney test.
Results
The two groups were comparable in age and sex. Patients yielded more cultivable bacterial species per subject than controls (mean 4.4 vs. 2.9; Mann–Whitney p < 0.001). Several species were numerically more frequent in patients (e.g., Staphylococcus hominis, S. lugdunensis) and others in controls (e.g., S. epidermidis, S. aureus), but no individual species difference remained significant after correction.
Conclusions
Using routine culture, CRSwNP was characterized chiefly by a higher number of cultivable bacterial species, whereas individual species differences were not statistically robust. These hypothesis-generating findings warrant confirmation in larger, sequencing-based studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Otolaryngology-Head and Neck Surgery, Ospedale San Camillo de Lellis, Azienda Sanitaria Locale (ASL) Rieti, Sapienza University of Rome, 02100 Rieti, Italy.
- Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
- Department of Sense Organs (DOS), Sapienza University of Rome, 00161 Rome, Italy.
- Clinical Pathology, San Camillo de Lellis Hospital, 02100 Rieti, Italy.
- Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR), 00161 Rome, Italy.
- Interdisciplinary Department of Well-Being, Health and Environmental Sustainability (BeSSA), Sapienza University of Rome, 02100 Rieti, Italy.
ORCID-Profile: Camilla Laureti, Dario Benelli, Federica Zoccali, Gabriele Riccardi, Christian Barbato, Carla Petrella
Förderung
- Bank of Italy
Zitieren
APA
Laureti, C., Benelli, D., Zoccali, F., Riccardi, G., Di Michele, M. U., Venarubea, S., Barbato, C., Minni, A., & Petrella, C. (2026). Culturable Nasal Bacteria in Chronic Rhinosinusitis with Nasal Polyps: A Single-Center Observational Pilot Study. Diseases, 14(7), 264. https://doi.org/10.3390/diseases14070264
Vancouver
Laureti C, Benelli D, Zoccali F, Riccardi G, Di Michele MU, Venarubea S, et al. Culturable Nasal Bacteria in Chronic Rhinosinusitis with Nasal Polyps: A Single-Center Observational Pilot Study. Diseases. 2026;14(7):264. doi:10.3390/diseases14070264
BibTeX
@article{Laureti2026,
author = {Laureti, Camilla and Benelli, Dario and Zoccali, Federica and Riccardi, Gabriele and Di Michele, Mattia Umberto and Venarubea, Stefano and Barbato, Christian and Minni, Antonio and Petrella, Carla},
title = {Culturable Nasal Bacteria in Chronic Rhinosinusitis with Nasal Polyps: A Single-Center Observational Pilot Study},
journal = {Diseases},
year = {2026},
volume = {14},
number = {7},
pages = {264},
doi = {10.3390/diseases14070264}
}
EUVIMED